Valuation: MYOS Corp

Market Cap 7.25M 6.43M 6.02M 5.46M 10.3M 699M 10.38M 72.3M 28.12M 356M 27.2M 26.62M 1.15B P/E 2021
-1.04x
P/E 2022 -0.41x
Enterprise Value 2.88M 2.55M 2.39M 2.17M 4.09M 277M 4.12M 28.71M 11.17M 142M 10.8M 10.57M 455M EV / Sales 2021
1.74x
EV / Sales 2022 0.46x
Free-Float
-
Yield 2021 *
-
Yield 2022 -

Financials

2021 2022
Net sales 22.13M 19.64M 18.38M 16.66M 31.47M 2.13B 31.7M 221M 85.87M 1.09B 83.06M 81.28M 3.5B 43.11M 38.27M 35.81M 32.46M 61.3M 4.16B 61.75M 430M 167M 2.12B 162M 158M 6.82B
Net income -43.82M -38.89M -36.4M -32.99M -62.31M -4.22B -62.76M -437M -170M -2.15B -164M -161M -6.93B -47.62M -42.27M -39.56M -35.85M -67.71M -4.59B -68.2M -475M -185M -2.34B -179M -175M -7.53B
Net Debt -7.44M -6.61M -6.18M -5.6M -10.58M -717M -10.66M -74.25M -28.88M -366M -27.93M -27.34M -1.18B -4.37M -3.88M -3.63M -3.29M -6.21M -421M -6.26M -43.59M -16.95M -215M -16.4M -16.05M -691M
Logo MYOS Corp
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Employees
-
Sector
-